A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKβ-NEMO interaction

Analytical Biochemistry

Volumn 405, Issue 1, 2010, Pages 19-27

  Gotoh, Yusuke ^a   Nagata, Hidetaka ^a   Kase, Hideo ^a   Shimonishi, Manabu ^a   Ido, Motoharu ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

High throughput screen (HTS); Homogeneous time resolved fluorescence (HTRF); I B kinase (IKK); NEMO binding domain (NBD); NF B; NF B essential modulator (NEMO); Time resolved fluorescence resonance energy transfer (TR FRET)

Indexed keywords

BINDING ENERGY; CELL ADHESION; ENERGY TRANSFER; ENZYMES; FORSTER RESONANCE ENERGY TRANSFER; MOLECULES; TRANSCRIPTION;

BINDING DOMAIN; CELL ADHESION MOLECULES; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH-THROUGHPUT SCREENING SYSTEMS; HIGH-THROUGHPUT SCREENS; NUCLEAR TRANSCRIPTION FACTORS; TIME-RESOLVED FLUORESCENCE; TR-FRET;

DISEASES;

BINDING PROTEIN; I KAPPA B; I KAPPA B KINASE BETA; NEMO BINDING DOMAIN; PROTEIN NF KAPPA ESSENTIAL MODULATOR; UNCLASSIFIED DRUG; I KAPPA B KINASE; IKBKG PROTEIN, HUMAN; PEPTIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG SCREENING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; PROCEDURES; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TIME;

CELL LINE; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; I-KAPPA B KINASE; IMMUNOPRECIPITATION; PEPTIDES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77955094923     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.05.028     Document Type: Article

References (28)

1. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Marin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997, 388:548-554.
2. Zandi E., Chen Y., Karin M. Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 1998, 281:1360-1363.
3. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997, 91:243-252.
4. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997, 278:860-866.
5. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 1998, 395:297-300.
6. Mercurio F., Murray B.W., Shevchenko A., Bennett B.L., Young D.B., Li J.W., Pascual G., Motiwala A., Zhu H., Mann M., Manning A.M. IκB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell. Biol. 1999, 19:1526-1538.
7. Krappmann D., Hatada E.N., Tegethoff S., Li J., Klippel A., Giese K., Baeuerle P.A., Scheidereit C. The IκB kinase (IKK) complex is tripartite and contains IKKγ but not IKAP as a regular component. J. Biol. Chem. 2000, 275:29779-29787.
8. Li X.H., Fang X., Gaynor R.B. Role of IKKγ/NEMO in assembly of the IκB kinase complex. J. Biol. Chem. 2001, 276:4494-4500.
9. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., Kirk H.E., Kay R.J., Israel A. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 1998, 93:1231-1240.
10. Ye J., Xie X., Tarassishin L., Horwitz M.S. Regulation of the NF-κB activation pathway by isolated domains of FIP3/IKKγ, a component of the IκB-α kinase complex. J. Biol. Chem. 2000, 275:9882-9889.
11. May M.J., D'Acquisto F., Medge L.A., Glockner J., Pober J.S., Ghosh S. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 2000, 289:1550-1554.
12. May M.J., Marienfeld R.B., Ghosh S. Characterization of the IκB-kinase NEMO binding domain. J. Biol. Chem. 2002, 277:45992-46000.
13. Strickland I., Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann. Rheum. Dis. 2006, 65:75-82.
14. Rehman K.K., Bertera S., Bottino R., Balamurugan A.N., Mai J.C., Mi Z., Trucco M., Robbins P.D. Protection of islets by in situ peptide-mediated transduction of the IκB kinase inhibitor NEMO-binding domain peptide. J. Biol. Chem. 2003, 278:9862-9868.
15. Dasgupta S., Jana M., Zhou Y., Fung Y.K., Ghosh S., Pahan K. Antineuroinflammatory effect of NF-κB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J. Immunol. 2004, 173:1344-1354.
16. Dai S., Hirayama T., Abbas S., Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 2004, 279:37219-37222.
17. di Meglio P., Ianaro A., Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis Rheum. 2005, 52:951-958.
18. Dave S.H., Tilstra J.S., Matsuoka K., Li F., Karrasch T., Uno J.K., Sepulveda A.R., Jobin C., Baldwin A.S., Robbins P.D., Plevy S.E. Amelioration of chronic murine colitis by peptide-mediated transduction of the IκB kinase inhibitor NEMO binding domain peptide. J. Immunol. 2007, 179:7852-7859.
19. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., Okabe K., Ohya K., Ghosh S. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 2004, 10:617-624.
20. Tas S.W., de Jong E.C., Haiji N., May M.J., Ghosh S., Vervoordeldonk M.J., Tak P.P. Selective inhibition of NF-κB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur. J. Immunol. 2005, 35:1164-1174.
21. Marienfeld R.B., Palkowitsch L., Ghosh S. Dimerization of the IκB kinase-binding domain of NEMO is required for tumor necrosis factor α-induced NF-κB activity. Mol. Cell. Biol. 2006, 26:9209-9219.
22. Rushe M., Silvian L., Bixler S., Chen L.L., Cheung A., Bowes S., Cuervo H., Berkowitz S., Zheng T., Guckian K., Pellegrini M., Lugovskoy A. Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure 2008, 16:798-808.
23. Bernier M., Kwon Y.K., Pandey S.K., Zhu T.N., Zhao R.J., Maciuk A., He H.J., Decabo R., Kole S. Binding of manumycin A inhibits IκB kinase beta activity. J. Biol. Chem. 2006, 281:2551-2561.
24. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
25. Strnad J., Burke J.R. IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol. Sci. 2007, 28:142-148.
26. Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 2008, 14:5656-5662.
27. Neiderberger E., Geisslinger G. The IKK-NF-κB pathway: a source for novel molecular drug targets in pain therapy?. FASEB J. 2008, 10:3432-3442.
28. Rudolph D., Yeh W.C., Wakeham A., Rudolph B., Nallainathan D., Potter J., Elia A.J., Mak T.W. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev. 2000, 14:854-862.